Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.
BACKGROUND
Inhalation of hypertonic nebulised colistin causes chest tightness and is a reason for discontinuing the treatment. This study examines the relationship of chest tightness and change in lung function in response to the inhalation of a range of tonicities of nebulised colistin and their influence on patients' preference.


METHODS
Twenty seven adult patients with cystic fibrosis and a mean forced expiratory volume in one second (FEV1) of 54% predicted (range 24-98) were studied. They inhaled a nebulised solution of hypertonic, isotonic, and hypotonic colistin over three consecutive days in random order in a double blind fashion. Measurements of chest tightness, using a visual analogue scale (VAS), and FEV1 were recorded before and 0, 15, 30, 60, and 90 minutes following inhalation. The solution preferred by each patient was determined at the end of the three days.


RESULTS
All tonicities caused a significant fall in FEV1 % predicted and an increase in chest tightness, with no differences between the solutions. However, the mean (SE) time to the maximum fall in FEV1 % predicted was significantly different between the solutions (hypertonic 7.8 (2.1) min, isotonic 19.2 (5.5) min, and hypotonic 34.2 (5.9) min) with a mean difference (95% CI) between hypotonic and hypertonic solutions of 28.04 (14.6 to 41.5) min, between isotonic and hypertonic solutions of 12.0 (-0.1 to 24.1) min, and between hypotonic and isotonic solutions of 15.6 (1.8 to 29.4) min. Positive correlations existed for the maximum fall in FEV1 % predicted between the hypertonic and isotonic solutions (r = 0.62, p < 0.001) and between the hypotonic and isotonic solutions (r = 0.64, p < 0.001). There was no correlation between the objective and subjective measurements for any solution. The patients' preference varied.


CONCLUSIONS
All tonicities of colistin caused equal symptoms of chest tightness and reduction in pulmonary function. It is recommended that the patient is challenged with nebulised colistin before prescription of the drug and that the challenge is preceded by an inhaled bronchodilator. Most of the patients preferred the isotonic or hypotonic solutions. The isotonic solution reflects a fall in FEV1 representative of all the solutions. The fall in FEV1 to the hypotonic solution occurred over a longer period and may be better tolerated by some patients.
Dodd
M E
ME
Bradbury Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, UK.
Abbott
J
J
Maddison
J
J
Moorcroft
A J
AJ
Webb
A K
AK
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003091:Colistin / Q000008:administration & dosage / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000503:physiopathology*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D006982:Hypertonic Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D007552:Isotonic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D018709:Statistics, Nonparametric; D013997:Time Factors
D000900:Anti-Bacterial Agents; D006982:Hypertonic Solutions; D007552:Isotonic Solutions; D003091:Colistin